Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort Study

Bingyu Zhang, Qiong Wu, Ravi Jhaveri, Ting Zhou, Michael J. Becich, Yuriy Bisyuk, Frank Blanceró, Elizabeth A. Chrischilles, Cynthia H. Chuang, Laura Cowell, Daniel Fort, Carol R. Horowitz, Susan Kim, Nathalia Ladino, David Liebovitz, Mei Liu, Abu Saleh Mohammad Mosa, Hayden T. Schwenk, Srinivasan Suresh, Bradley Taylor, David A. Williams, Jeffrey S. Morris, Christopher R. Forrest, Yong ChenmedRxiv 2025 · DOI

TL;DR

A massive study of over 460,000 pediatric patients reveals that SARS-CoV-2 reinfection during the Omicron era significantly increases the risk of Long COVID (PASC). Compared to a first infection, a second infection roughly doubles the risk of a PASC diagnosis and elevates the risk for 24 specific clinical conditions across multiple organ systems.

What Problem Does This Paper Address?

While the acute severity of COVID-19 has generally decreased with the emergence of Omicron variants, the frequency of reinfections has skyrocketed. Most existing research on Post-Acute Sequelae of SARS-CoV-2 (PASC)—commonly known as "Long COVID"—has focused on the aftermath of a person's first infection.

There has been a critical knowledge gap regarding whether subsequent infections carry a lower, equal, or higher risk of long-term complications, especially in children and adolescents. This paper addresses this gap by investigating if the risk of PASC is "cumulative," meaning each successive infection adds to the likelihood of developing chronic symptoms.

Methods

The researchers conducted a retrospective cohort study using electronic health records (EHR) from the RECOVER consortium, which includes 40 pediatric institutions across the U.S.

To ensure a fair comparison between "first infection" and "second infection" groups, they employed a rigorous two-step statistical approach:

  1. Exact Matching: Patients were matched based on age group, sex, race/ethnicity, clinical site, vaccine doses, and the month they entered the study.
  2. Propensity Score Matching (PSM): Within those matched groups, they used logistic regression to balance hundreds of additional covariates, including pre-existing chronic conditions, obesity, and healthcare utilization patterns (like the number of previous hospital visits).

They defined PASC in two ways: through the official ICD-10 diagnosis code (U09.9) and via a list of 24 physician-identified symptoms and conditions (e.g., myocarditis, fatigue, cognitive dysfunction) occurring between 28 and 179 days after infection.

Datasets

The study utilized the RECOVER-EHR Database (Version s10), standardized to the PCORnet Common Data Model.

  • Total Population: 465,717 individuals under age 21.
  • First Infection Group: 407,300 patients.
  • Second Infection Group: 58,417 patients.
  • Timeframe: January 1, 2022, to October 13, 2023 (the Omicron era).

Key Insights and Ideas

  • The "Cumulative Risk" Hypothesis: The most striking takeaway is that PASC risk appears to be cumulative. A second infection isn't "safer" just because the body has seen the virus before; instead, it significantly increases the probability of new long-term health issues.
  • Broad Systemic Impact: The increased risk isn't confined to a single organ. Reinfection was associated with higher risks in cardiovascular, respiratory, gastrointestinal, neurological, and musculoskeletal systems.
  • Vaccination and Severity as Modifiers: Interestingly, the heightened risk of PASC following reinfection remained consistent regardless of the patient's vaccination status or the severity of their acute symptoms during the second bout. Even "mild" reinfections contributed to PASC risk.
  • Immunological Waning: The authors suggest these findings align with evidence that while T-cell memory remains robust, neutralizing antibody responses (B-cell) wane over time, potentially leaving the body vulnerable to the systemic inflammatory processes that drive PASC.

Key Results

The study found that a second infection was associated with a Relative Risk (RR) of 2.08 for an overall PASC diagnosis compared to a first infection.

Specific conditions showed even higher relative risks:

  • Myocarditis: RR 3.60 (The highest observed risk).
  • Changes in Taste and Smell: RR 2.83.
  • Thrombophlebitis/Thromboembolism: RR 2.28.
  • Acute Kidney Injury: RR 1.90.
  • Fatigue and Malaise: RR 1.50.
  • Cognitive Functions: RR 1.32.

In absolute terms, the incidence rate for a PASC diagnosis jumped from 903.7 per million persons (after the first infection) to 1883.7 per million (after the second).

Limitations and Future Work

The authors acknowledge several limitations inherent in EHR-based research:

  • Misclassification: Asymptomatic or very mild cases might not be recorded in the EHR, potentially leading to undercounting of the total infected population.
  • Healthcare Utilization Bias: Patients who have had multiple infections might interact with the healthcare system more frequently, increasing the "opportunity" for a PASC diagnosis (though the researchers tried to control for this).
  • Generalizability: Some racial and ethnic groups were underrepresented in the data.
  • Duration: The study did not investigate the timing of onset or how long these symptoms persisted (resolution vs. permanence).

Future research is needed to understand the biological mechanisms behind this cumulative risk and to identify specific high-risk pediatric subgroups for targeted intervention.

Summary updated

Abstract

Abstract IMPORTANCE Post-acute sequelae of SARS-CoV-2 infection (PASC) remains a major public health challenge. While previous studies have focused on characterizing PASC and identifying its subphenotypes in children and adolescents following an initial SARS-CoV-2 infection, the risks of PASC with Omicron-variant reinfections remain unclear. Using a real-world data approach, this study investigates the risks of PASC following reinfections during the Omicron phase in the pediatric population. OBJECTIVE To investigate the risks of PASC diagnosis and 24 PASC symptoms and conditions after reinfection of SARS-CoV-2 during Omicron period in the pediatric population. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used data from the RECOVER consortium comprising 40 children’s hospitals and health institutions in U.S. between January 2022 and October 2023. EXPOSURES A second SARS-CoV-2 infection, confirmed by a positive polymerase-chain-reaction (PCR) or antigen tests, or a diagnose of COVID-19, occurring at least 60 days after the initial infection, compared to the initial infection. MAIN OUTCOMES AND MEASURES PASC was identified using two approaches: (1) the ICD-10- CM diagnosis code U09.9 and (2) a symptom-based definition including 24 physician-identified symptoms and conditions. Absolute risks of incident PASC were reported, and relative risks (RRs) were calculated by comparing the second infection episode with the first infection episode groups using a modified Poisson regression model, adjusting for demographic, clinical, and healthcare utilization factors through exact matching and propensity scoring matching. RESULTS A total of 465,717 individuals under 21 years old (mean [SD] age 8.17 [6.58] years; 52% male) were included. Compared to the first infection, a second infection was associated with significantly increased risk of an overall PASC diagnosis (RR, 2.08; 95% confidence interval [CI], 1.68-2.59), and with many specific conditions including: myocarditis (RR, 3.60; 95% CI, 1.46-8.86); changes in taste and smell (RR, 2.83; 95% CI, 1.41-5.67); thrombophlebitis and thromboembolism (RR, 2.28; 95% CI, 1.71-3.04); heart disease (RR, 1.96; 95% CI, 1.69 to 2.28); acute kidney injury (RR, 1.90; 95% CI, 1.38 to 2.61); fluid and electrolyte (RR, 1.89; 95% CI, 1.62 to 2.20); generalized pain (RR, 1.70; 95% CI, 1.48 to 1.95); arrhythmias (RR, 1.59; 95% CI, 1.45-1.74); abnormal liver enzyme (RR, 1.56; 95% CI, 1.24 to 1.96); fatigue and malaise (RR, 1.50; 95% CI, 1.38 to 1.64); musculoskeletal pain (RR, 1.45; 95% CI, 1.37 to 1.54); abdominal pain (RR, 1.42; 95% CI, 1.34 to 1.50); postural orthostatic tachycardia syndromes (POTS)/dysautonomia (RR, 1.35; 95% CI, 1.20 to 1.51); cognitive functions (RR, 1.32; 95% CI, 1.15 to 1.50); and respiratory signs and symptoms (RR, 1.29; 95% CI, 1.25 to 1.33). The risks were consistent across various organ systems, including cardiovascular, respiratory, gastrointestinal, neurological, and musculoskeletal systems. CONCLUSIONS AND RELEVANCE Children and adolescents face significantly higher risk of various PASC outcomes after reinfection with SARS-CoV-2. These findings suggest a cumulative risk of PASC and highlight the urgent need for targeted prevention strategies to reduce reinfections, which includes an increased emphasis on initial or re-vaccination of children. Key Points Question Do children and adolescents face an increased risk of post-acute sequelae of SARS-CoV-2 infection (PASC) following reinfection during the Omicron era? Findings During the post-acute phase, children and adolescents with reinfection are at statistically significant increased risk of incident PASC outcomes, including an overall PASC diagnosis and 24 most commonly complaints/symptoms/diagnoses associated with PASC. The risks remained consistent across different demographic and clinical subgroups. Meaning These findings underscore the significant long-term health risks associated with SARS-CoV-2 reinfection in children and adolescents. Public health strategies should prioritize reinfection prevention, including enhanced vaccination efforts, to mitigate the burden of PASC in the pediatric population.
BibTeX
@misc{zhang2025reinfection,
  author = {Bingyu Zhang and Qiong Wu and Ravi Jhaveri and Ting Zhou and Michael J. Becich and Yuriy Bisyuk and Frank Blanceró and Elizabeth A. Chrischilles and Cynthia H. Chuang and Laura Cowell and Daniel Fort and Carol R. Horowitz and Susan Kim and Nathalia Ladino and David Liebovitz and Mei Liu and Abu Saleh Mohammad Mosa and Hayden T. Schwenk and Srinivasan Suresh and Bradley Taylor and David A. Williams and Jeffrey S. Morris and Christopher R. Forrest and Yong Chen},
  title = {{Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort Study}},
  year = {2025},
  doi = {10.1101/2025.03.28.25324858},
  howpublished = {medRxiv},
}
Figure